In this study, MET treatment upregulated the expression level of Irs1 and downregulated most of the genes (such as Il6r, Jak1, and Rptor) in the PI3K-Akt signaling pathway, which may contribute to improvements in T2D. The gene discussed is IL6R; the disease is type 2 diabetes mellitus.